Illustration of HLA-B with peptide in the binding pocket.
HLA-B (alpha)-β2MG with bound peptide
major histocompatibility complex (human), class I, B58
Alleles *5801, *5802
Structure (See HLA-B)
Shared data
Locus chr.6 6p21.31

HLA-B58 (B58) is an HLA-B serotype. B58 is a split antigen from the B17 broad antigen, the sister serotype B57.[1] The serotype identifies the more common HLA-B*58 gene products.[2] (For terminology help see: HLA-serotype tutorial) B*5801 is associated with allopurinol induced inflammatory necrotic skin disease.

SerotypeEdit

B58 and B17 serotype recognition of some more common HLA B*58 alleles[3]
B*58 B58 B17 Sample
allele % % size (N)
*5801 79 4 2096
*5802 72 3 837

Allele distributionEdit

HLA B*5801 frequencies
freq
ref. Population (%)
[4] Cameroon Pygmy Baka 15.0
[4] India Khandesh Pawra 15.0
[4] Cameroon Sawa 11.5
[4] Taiwan Hakka 10.9
[4] Kenya Nandi 10.0
[4] India West Bhils 9.0
[4] China South Han 8.9
[4] China Inner Mongolia 8.8
[4] India North Delhi 8.8
[4] Thailand Northeast 8.4
[4] Guinea Bissau 7.8
[4] Thailand 7.7
[4] India Mumbai Marathas 7.4
[4] India Andhra Pradesh Golla 7.2
[4] Kenya Luo 7.0
[4] Senegal Niokholo Mandenka 6.9
[4] India New Delhi 6.8
[4] Oman 6.8
[4] Russia Tuva (2) 6.7
[4] South Korea (3) 6.5
[4] Italy Sardinia (3) 6.4
[4] Burkina Faso Fulani 6.1
[4] Taiwan Siraya 5.9
[4] India North Hindus 5.8
[4] Burkina Faso Mossi 5.7
[4] Cameroon Yaounde 5.4
[4] Cameroon Bamileke 5.2
[4] Singapore Riau Malay 5.0
[4] Saudi Arabia Guraiat and Hail 4.6
[4] France Corsica 4.5
[4] Sudanese 4.5
[4] Zimbabwe Harare Shona 4.4
[4] Burkina Faso Rimaibe 4.3
[4] Iran Baloch 4.0
[4] South African Natal Zulu 4.0
[4] Tunisia 4.0
[4] Uganda Kampala 4.0
[4] Cameroon Beti 3.7
[4] Tunisia Ghannouch 3.7
[4] Taiwan Pazeh 3.6
[4] Tunisia Tunis 3.4
[4] Italy North (1) 3.3
[4] Israel Ashkenazi and Non Ashkenazi Jews 3.2
[4] India West Coast Parsis 3.0
[4] China North Han 2.9
[4] Ivory Coast Akan Adiopodoume 2.3
[4] Mali Bandiagara 2.2
[4] Mexico Zaptotec Oaxaca 2.2
[4] South Africa Natal Tamil 2.0
[4] China Yunnan Nu 1.9
[4] Bulgaria 1.8
[4] China Tibet Autonomous Region Tibetans 1.6
[4] France South East 1.6
[4] Israel Arab Druse 1.5
[4] Czech Republic 1.4
[4] Georgia Tibilisi Georgians 1.4
[4] Jordan Amman 1.4
[4] Morocco Nador Metalsa (berber) 1.4
[4] Croatia 1.3
[4] Romanian 1.3
[4] Spain Eastern Andalusia 1.2
[4] Australian Aborigine Cape York Peninsula 1.0
B*5802
[4] Cameroon Bamileke 14.3
[4] Kenya Luo 12.5
[4] Cameroon Yaounde 10.9
[4] Cameroon Pygmy Baka 10.0
[4] Cameroon Beti 9.8
[4] Kenya Nandi 8.5
[4] South African Natal Zulu 8.5
[4] Cameroon Sawa 7.7
[4] Zimbabwe Harare Shona 6.4
[4] Cape Verde Northwestern Islands 5.6
[4] Uganda Kampala 4.4
[4] Central Africa Republic Mbenzele Pygmy 4.0
[4] Zambia Lusaka 2.3
[4] Iran Baloch 1.0
[4] Tunisia 1.0

DiseaseEdit

HLA-B*5801 is involved in allopurinol sensitive drug induced Stevens–Johnson syndrome.[5][6] Allopurinol is a frequent cause of severe cutaneous adverse reactions, including drug-hypersensitivity syndrome, Stevens–Johnson syndrome, and toxic epidermal necrolysis (SJS/TEN).[7] The association with allopurinol sensitivity in SJS/TEN was extremely strong in Asia, and somewhat less associated in Europeans.[8]

ReferencesEdit

  1. ^ Ways JP, Coppin HL, Parham P (1985). "The complete primary structure of HLA-Bw58". J. Biol. Chem. 260 (22): 11924–33. PMID 2995352.
  2. ^ Marsh, S. G.; Albert, E. D.; Bodmer, W. F.; Bontrop, R. E.; Dupont, B.; Erlich, H. A.; Fernández-Viña, M.; Geraghty, D. E.; Holdsworth, R.; Hurley, C. K.; Lau, M.; Lee, K. W.; Mach, B.; Maiers, M.; Mayr, W. R.; Müller, C. R.; Parham, P.; Petersdorf, E. W.; Sasazuki, T.; Strominger, J. L.; Svejgaard, A.; Terasaki, P. I.; Tiercy, J. M.; Trowsdale, J. (2010). "Nomenclature for factors of the HLA system, 2010". Tissue Antigens. 75 (4): 291–455. doi:10.1111/j.1399-0039.2010.01466.x. PMC 2848993. PMID 20356336.
  3. ^ derived from IMGT/HLA
  4. ^ a b c d e f g h i j k l m n o p q r s t u v w x y z aa ab ac ad ae af ag ah ai aj ak al am an ao ap aq ar as at au av aw ax ay az ba bb bc bd be bf bg bh bi bj bk bl bm bn bo bp bq br bs bt bu bv bw bx by Middleton D, Menchaca L, Rood H, Komerofsky R (2003). "New allele frequency database: http://www.allelefrequencies.net". Tissue Antigens. 61 (5): 403–7. doi:10.1034/j.1399-0039.2003.00062.x. PMID 12753660. External link in |title= (help)
  5. ^ Chung WH, Hung SI, Chen YT (August 2007). "Human leukocyte antigens and drug hypersensitivity". Curr Opin Allergy Clin Immunol. 7 (4): 317–23. doi:10.1097/ACI.0b013e3282370c5f. PMID 17620823.
  6. ^ Tassaneeyakul W, Jantararoungtong T, Chen P, Lin PY, Tiamkao S, Khunarkornsiri U, Chucherd P, Konyoung P, Vannaprasaht S, Choonhakarn C, Pisuttimarn P, Sangviroon A, Tassaneeyakul W (2009). "Strong association between HLA-B*5801 and allopurinol-induced Stevens–Johnson syndrome and toxic epidermal necrolysis in a Thai population". Pharmacogenet Genomics. 19 (9): 704–9. doi:10.1097/FPC.0b013e328330a3b8. PMID 19696695.
  7. ^ Hung SI, Chung WH, Liou LB, et al. (March 2005). "HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol". Proc. Natl. Acad. Sci. U.S.A. 102 (11): 4134–9. doi:10.1073/pnas.0409500102. PMC 554812. PMID 15743917.
  8. ^ Lonjou C, Borot N, Sekula P, et al. (February 2008). "A European study of HLA-B in Stevens–Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs". Pharmacogenet. Genomics. 18 (2): 99–107. doi:10.1097/FPC.0b013e3282f3ef9c. PMID 18192896.